Skip to main content
OpenTrials
Completed

NCT Number: NCT07743788

Efficacy, Satisfaction, and Safety of the Mesolipo® Protocol for the Treatment of Localized Adiposity

This randomized, split-body clinical trial aims to evaluate the efficacy, safety, and participant satisfaction of the Mesolipo® protocol for the treatment of localized adiposity. Participants will receive the Mesolipo® intervention on one side of the body and an active comparator on the contralateral side. Outcomes will be assessed through standardized clinical, photographic, ultrasonographic, and patient-reported measures over a 90-day follow-up period to determine treatment effectiveness and safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Localized Adiposity Behavior Health Behavior Patient Satisfaction Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Instituto Antony Barbosa

Belo Horizonte, Minas Gerais, 30493-240, Brazil

About this study

Introduction: The Mesolipo® Protocol is a promising alternative for the treatment of localized adiposity, a condition that may negatively affect self-esteem and quality of life. Combining the principles of mesotherapy and intralipotherapy, this minimally invasive method aims to reduce localized fat effectively and safely through the administration of lipolytic substances.

Objectives: This study aims to evaluate the efficacy, patient satisfaction, and safety of the Mesolipo® Protocol for the treatment of localized adiposity.

Methods: This is a controlled clinical study involving 12 participants. Each participant will receive the Mesolipo® treatment on one side of the body and placebo on the contralateral side, allowing an intra-individual comparison of outcomes. Efficacy will be assessed using skinfold measurements, standardized photographs, and the Global Aesthetic Improvement Scale. Patient satisfaction will be evaluated using specific questionnaires, while safety will be monitored through detailed documentation of adverse events and complications. Descriptive and analytical statistical analyses will be performed. The study will comply with ethical research principles and will begin only after approval by the Research Ethics Committee. Participation will be conditional upon signing the Informed Consent Form.

Expected Results: The study is expected to provide relevant evidence regarding the feasibility, efficacy, and safety of the Mesolipo® Protocol for the treatment of localized adiposity. The findings may support the development of new therapeutic options and contribute to improving the quality of life of individuals affected by this condition.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 years or older.
  • Presence of localized adiposity suitable for treatment with the Mesolipo® protocol.
  • Willingness and ability to provide written informed consent.
  • Ability to comply with all study procedures and follow-up visits.
  • Stable body weight for at least 3 months before enrollment.
  • Agreement to maintain usual diet and physical activity habits throughout the study.

Exclusion criteria

  • Pregnancy or breastfeeding.
  • Known hypersensitivity to sodium deoxycholate or any study product component.
  • Active infection or inflammatory skin disease at the treatment site.
  • Previous aesthetic treatment in the target area within the period defined by the protocol.
  • Severe systemic disease or any condition that, in the investigator's opinion, could interfere with study participation or outcome assessment.
  • Participation in another clinical trial within the previous 30 days.
  • Inability or unwillingness to comply with study procedures.

Treatment and study plan

Mesolipo®

Drug

Mesolipo® is an injectable formulation containing sodium deoxycholate administered by subcutaneous injection for the treatment of localized adiposity. The intervention is applied according to a standardized protocol regarding dose, injection technique, and treatment schedule.

Pentoxifylline

Drug

Pentoxifylline diluted in saline solution administered by subcutaneous injection using the same injection technique and treatment schedule as the experimental intervention. This intervention serves as the active comparator.

Primary outcomes

  1. Treatment efficacy

    Time frame: Baseline to Day 90

    Assessed by the reduction in skinfold thickness measured using standardized skinfold calipers.

  2. Treatment Safety

    Time frame: Baseline to day 90

    Safety will be assessed by the occurrence, frequency, and severity of treatment-related adverse events.

Secondary outcomes

  1. Patient satisfaction score assessed using a 5-point Likert satisfaction scale

    Time frame: Day 90

    Patient satisfaction will be assessed using a standardized 5-point Likert satisfaction scale at Day 90. Scores range from 1 (very dissatisfied) to 5 (very satisfied). The mean satisfaction score will be reported. Higher scores indicate greater patient satisfaction.

  2. Global Aesthetic Improvement Scale (GAIS) score

    Time frame: Baseline and Day 90

    Aesthetic improvement will be assessed by a blinded evaluator using the Global Aesthetic Improvement Scale (GAIS). GAIS is a 5-point scale ranging from -2 (much worse) to +2 (very much improved). The mean GAIS score will be reported. Higher scores indicate greater aesthetic improvement.

  3. Photographic improvement score based on standardized clinical photographs

    Time frame: Baseline and Day 90

    Standardized clinical photographs obtained at Baseline and Day 90 will be independently evaluated by two blinded assessors. Improvement will be rated using a predefined 5-point photographic improvement scale (0 = no improvement, 1 = slight improvement, 2 = moderate improvement, 3 = marked improvement, 4 = excellent improvement). The mean photographic improvement score will be reported. Higher scores indicate greater improvement in localized adiposity.

Sponsors and collaborators

Lead sponsor

Antony de Paula Barbosa

Other

Registry information

Official study title

Eficácia,Satisfação e Segurança do Protocolo Mesolipo® no Tratamento da Gordura Localizada: um Estudo Randomizado

Acronym: MESO-LA

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 4, 2026
Registry last updated
Aug 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.